Surgical oncologist Kelly K. Hunt, of MD Anderson Cancer Center, discusses how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and the role of sentinel lymph node dissection in the neoadjuvant setting.
Treating patients with triple-negative breast cancer (TNBC) remains a challenge because these tumors do not rely on hormone receptors or HER2 amplification for tumor growth.